Overview

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

Status:
COMPLETED
Trial end date:
2025-01-13
Target enrollment:
Participant gender:
Summary
This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
AbbVie
Treatments:
Itraconazole